Join the Schizophrenia group to help and get support from people like you.
Schizophrenia News (Page 5)
Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia
FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the...
Allergan Receives FDA Approval for Vraylar (cariprazine) in the Maintenance Treatment of Schizophrenia
DUBLIN, Nov. 13, 2017 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar...
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
FDA Medwatch Alert: Paliperidone Extended-Release Tablets 3mg by Teva Pharmaceuticals: Recall - Dissolution Test Failure
ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A,...
FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil)...
Sunovion’s Latuda (lurasidone) Receives FDA Approval to Treat Adolescents with Schizophrenia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--January 28, 2017 Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug...
U.S. FDA Approves Labeling Update of Rexulti (brexpiprazole) for Maintenance Treatment of Schizophrenia
Princeton, New Jersey and Valby, Denmark – September 23, 2016 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food a...
FDA Medwatch Alert: Olanzapine: Drug Safety Communication - FDA Warns About Rare But Serious Skin Reactions
ISSUE: FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. FDA is adding a new warning to the...
FDA Medwatch Alert: Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems
ISSUE: FDA is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify...
FDA Approves Aristada (aripiprazole lauroxil) for Schizophrenia
October 6, 2015 – On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is...
FDA Approves Vraylar (cariprazine) for Schizophrenia and Bipolar Disorder
September 17, 2015 – The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. “Schizophrenia and bipolar disorder c...
FDA Medwatch Alert: Clozapine: Drug Safety Communication - FDA Modifies Monitoring for Neutropenia; Approves New Shared REMS Program
ISSUE: FDA is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current...
FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder
Tokyo, Japan and Valby, Denmark – July 11, 2015 –Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved Rex...
FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia
TITUSVILLE, N.J., May 19, 2015 – There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered j...
FDA Medwatch Alert: Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication - FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug
ISSUE: FDA has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died....
Further information
Related condition support groups
Related drug support groups
Seroquel, Abilify, Latuda, quetiapine, Vraylar, olanzapine, risperidone, Zyprexa, aripiprazole, view more... Risperdal, Rexulti, Seroquel XR, Geodon, Invega, Invega Sustenna